Assessing the Economic Attractiveness of Coronary Artery Revascularization in Chronic Kidney Disease Patients

Chronic kidney disease (CKD) is associated with increased morbidity and mortality in coronary artery disease (CAD) patients. We compared the economic attractiveness of CAD revascularization procedures in patients with and without CKD. Our population included 6218 patients with significant CAD undergoing cardiac catheterization at Duke University between 1996 and 2001, with follow-up through 2002. We investigated the influence of CKD (creatinine clearance < 60 mL/min) upon 3-year survival and medical costs in our CAD population. Coronary artery bypass graft (CABG) surgery was an economically attractive alternative vs. percutaneous coronary intervention (PCI) or medical therapy for all patients with left main disease, three-vessel CAD patients without CKD, and two-vessel CAD patients with CKD. Medical therapy was an economically attractive strategy vs. CABG surgery or PCI for three-vessel CAD patients with CKD, two-vessel CAD patients without CKD, and all single-vessel CAD patients.

[1]  J. Alpert,et al.  ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). , 1999, Circulation.

[2]  K A Eagle,et al.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.

[3]  A S Kosinski,et al.  A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). , 1995, Circulation.

[4]  R. Califf,et al.  Outcomes of Patients With Chronic Renal Insufficiency in the Bypass Angioplasty Revascularization Investigation , 2002, Circulation.

[5]  R. Califf,et al.  Economic impact of drug-eluting stents on hospital systems: a disease-state model. , 2004, American heart journal.

[6]  James T. Willerson,et al.  Appointment of New Associate Editor for Circulation , 1996 .

[7]  Robert M Califf,et al.  Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. , 2003, Journal of the American Society of Nephrology : JASN.

[8]  V. Hasselblad,et al.  Assessing the Clinical and Economic Burden of Coronary Artery Disease: 1986-1998 , 2001, Medical care.

[9]  E. Topol,et al.  Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features , 2004, Circulation.

[10]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  B. Gersh,et al.  Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina: Review of the Evidence and Methodological Considerations , 2003, Circulation.

[12]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[13]  A. Tsiatis,et al.  Utilizing Propensity Scores to Estimate Causal Treatment Effects with Censored Time‐Lagged Data , 2001, Biometrics.

[14]  R. Califf,et al.  Differential survival after coronary revascularization procedures among patients with renal insufficiency. , 2001, Kidney international.

[15]  G. Guyatt,et al.  Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials , 2000, BMJ : British Medical Journal.

[16]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[17]  D. Mark,et al.  Medical economics and the assessment of value in cardiovascular medicine: Part I. , 2002, Circulation.

[18]  D. Mark,et al.  Medical economics and the assessment of value in cardiovascular medicine: Part II. , 2002, Circulation.

[19]  F. Harrell,et al.  Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. , 1994, Circulation.

[20]  R. Califf,et al.  Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. , 1996, The Journal of thoracic and cardiovascular surgery.

[21]  R. Califf,et al.  The way of the future redux. , 1995, The American journal of cardiology.

[22]  J. A. Purcell,et al.  Percutaneous Transluminal Coronary Angioplasty , 1981, The American journal of nursing.

[23]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[24]  E. Hannan,et al.  A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. , 1999, Journal of the American College of Cardiology.

[25]  J. Madias.  Bypass angioplasty revascularization investigation. , 1997, The New England journal of medicine.

[26]  C F Starmer,et al.  A new information system for medical practice. , 1975, Archives of internal medicine.

[27]  J. Willerson.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.

[28]  D. Mark,et al.  Quality of Coronary Disease Report Cards , 2004 .

[29]  L. Smith,et al.  Preoperative determinants of postoperative costs associated with coronary artery bypass graft surgery. , 1994, Circulation.

[30]  F. Harrell,et al.  The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. , 1989, JAMA.

[31]  D. Mark,et al.  Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. , 1997, The New England journal of medicine.

[32]  F. Harrell,et al.  Survival in medically treated coronary artery disease. , 1979, Circulation.